Drug Maker Simcere Ditches Cell Therapy to Focus on Oncology
Company sells money-losing Simgene unit for $16 million, following recent deals to commercialize two new cancer drugs in China Key Takeaways: New China licensing deals and oncology focus come amid…
Recent Articles
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
